Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited said on Jul, 14 2026 that it expects net profit attributable to equity holders for the six months ended Jun, 30 2026 to come in between about S$119 million and S$127 million, a year-on-year decline of roughly 68 per cent to 66 per cent.

The forecast compares with the S$371 million recorded in the same period a year earlier.

Excluding non-recurring items, core net profit is projected at S$117 million to S$125 million, representing a 2 per cent to 9 per cent rise from the S$115 million booked in the first half of 2025.

The company attributed the sharp drop in headline earnings to the absence of a one-off after-tax gain of about S$252 million recognised in 1H 2025 from the disposal of its remaining 12 per cent stake in Tianjin TSKF Pharmaceutical to Haleon China and Haleon CH SARL.

Da Ren Tang noted that the figures are preliminary and unaudited; full interim results will be released in due course. Investors were advised to exercise caution when dealing in the company’s shares.